Market Cap 20.32B
Revenue (ttm) 8.26M
Net Income (ttm) -299.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,629.18%
Debt to Equity Ratio 0.00
Volume 4,244,389
Avg Vol 5,597,082
Day's Range N/A - N/A
Shares Out 719.27M
Stochastic %K 7%
Beta 1.13
Analysts Strong Sell
Price Target $39.04

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7400 3347
Website: roivant.com
Address:
50 Broadway, 7th Floor, London, United Kingdom
supplySHOCK
supplySHOCK Jun. 4 at 11:10 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 11:42 PM
0 · Reply
DocPharm
DocPharm May. 25 at 8:46 PM
$ABUS @Heavey the premium would be too insane to go private; especially with Genevant’s worth alone 16% plus the royalty rate on 10s of billions of revenue via Genevant’s inked deals - non-Covid related (not related to Pfizer or Moderna) Then factor in Moderna settlement; likely Pfizer settlement at 2-3x; worth of Imdusiran with fast track; worth of AB-101; worth of their Covid antiviral that has activity against HIV You’re looking at way too hefty of a price tag Remember $ROIV is technically under water by about $3 on the shares they own
2 · Reply
Blueviking
Blueviking May. 24 at 11:37 AM
$ABUS $ROIV Big boyzz been sending this up and down for 2-3 years aquiring shares. They now hav 95 percent of them. Imo, close to a big run up soon, which has been their plan 2-3 years Its not coincidental!
1 · Reply
mj6534
mj6534 May. 22 at 10:41 PM
$ABUS it’s funny I looked at $ROIV forever ago at 4-5$ and was like “I should grab a few Shares. Welp we all should’ve bought them instead of ABUS considering we are being used to push them up. I hope androski realizes what a POS she is.
5 · Reply
Alfalcon
Alfalcon May. 22 at 5:44 PM
$ROIV TD Cowen raises PT >41
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
renoH4
renoH4 May. 21 at 12:38 PM
$ROIV ...and Arbutus against EBOLA ? "WORLD WAR Z" Arbutus developed LNP Technology and it was Ahead of Its Time Interestingly, Tekmira/Arbutus was one of the early pioneers of LNP technology—a technology that later became crucial for mRNA vaccines as well. The expertise gained from these Ebola programs indirectly contributed to subsequent RNA-based therapeutics and vaccine platforms. Theoretically, it would be possible to develop an adapted RNAi formulation targeting a new Ebola strain. Today, this could be accomplished even faster than it was in 2014. Hope they will find together a way and develop a medicin!
0 · Reply
Quantumup
Quantumup May. 21 at 10:33 AM
BofA⬆️ $IMVT's PT to $43 and reiterated at Buy $ROIV $ARGX JNJ LLY - INCY ABBV UCBJY AZN BofA said: We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8BN (vs. $5.5BN prior), driven by greater contribution from GD & D2T RA-both large 'white-space' TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SJD are sizable markets, we assign lower value due to higher clinical/competitive risk. We also reduce 1402 peak sales in FcRn-entrenched markets (MG, CIDP). See Exhibit 1 for updated risk-adjusted SOTP DCF. We reiterate Buy as in our view 1402's opportunity remains underappreciated.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:28 AM
$ROIV Roivant Sciences surged after swinging to profitability and moving closer to a potential brepocitinib launch. Here’s why ROIV stock suddenly became one of the most-watched biotech movers. https://globalmarketbulletin.com/is-roivant-sciences-roiv-a-good-biotech-stock-to-buy-before-its-next-fda-catalyst/
0 · Reply
Latest News on ROIV
Roivant Sciences price target raised to $42 from $35 at Citi

2026-05-21T11:03:04.000Z - 14 days ago

Roivant Sciences price target raised to $42 from $35 at Citi


Roivant Sciences rises 15.2%

2026-05-20T16:05:53.000Z - 15 days ago

Roivant Sciences rises 15.2%


Roivant Sciences rises 11.7%

2026-05-20T14:08:44.000Z - 15 days ago

Roivant Sciences rises 11.7%


Roivant Sciences Earnings Call Transcript: Q4 2026

May 20, 2026, 8:00 AM EDT - 15 days ago

Roivant Sciences Earnings Call Transcript: Q4 2026


Roivant Sciences Annual report: Q4 2026

May 20, 2026, 8:00 AM EDT - 15 days ago

Roivant Sciences Annual report: Q4 2026


Roivant Sciences Slides: Q4 2026

May 20, 2026, 8:00 AM EDT - 15 days ago

Roivant Sciences Slides: Q4 2026


Roivant Sciences Earnings release: Q4 2026

May 20, 2026, 8:00 AM EDT - 15 days ago

Roivant Sciences Earnings release: Q4 2026


Roivant Sciences reports Q4 EPS 28c, consensus (35c)

2026-05-20T11:10:39.000Z - 15 days ago

Roivant Sciences reports Q4 EPS 28c, consensus (35c)


Roivant Sciences assumed with an Overweight at Piper Sandler

2026-04-16T14:07:55.000Z - 7 weeks ago

Roivant Sciences assumed with an Overweight at Piper Sandler


Roivant Sciences Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Roivant Sciences Transcript: Study result


Roivant Sciences Press release: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Roivant Sciences Press release: Study result


Roivant Sciences Slides: Study result

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Roivant Sciences Slides: Study result


Roivant Sciences initiated with an Outperform at Bernstein

2026-03-19T20:22:56.000Z - 2 months ago

Roivant Sciences initiated with an Outperform at Bernstein


Roivant Sciences Transcript: Status update

Mar 3, 2026, 4:45 PM EST - 3 months ago

Roivant Sciences Transcript: Status update


Roivant Sciences Press release: Status update

Mar 3, 2026, 4:45 PM EST - 3 months ago

Roivant Sciences Press release: Status update


Roivant Sciences Slides: Status update

Mar 3, 2026, 4:45 PM EST - 3 months ago

Roivant Sciences Slides: Status update


Roivant Sciences Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Roivant Sciences Earnings Call Transcript: Q3 2026


Roivant Sciences Quarterly report: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Roivant Sciences Quarterly report: Q3 2026


Roivant Sciences Earnings release: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Roivant Sciences Earnings release: Q3 2026


Roivant Sciences Slides: Q3 2026

Feb 6, 2026, 8:00 AM EST - 4 months ago

Roivant Sciences Slides: Q3 2026


Roivant Sciences Transcript: Investor Day 2025

Dec 11, 2025, 8:00 AM EST - 6 months ago

Roivant Sciences Transcript: Investor Day 2025


Roivant Sciences Slides: FY 2025

Dec 11, 2025, 8:00 AM EST - 6 months ago

Roivant Sciences Slides: FY 2025


Roivant Sciences Slides: Corporate Presentation

Nov 10, 2025, 6:00 PM EST - 7 months ago

Roivant Sciences Slides: Corporate Presentation


Roivant Sciences Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Earnings Call Transcript: Q2 2026


Roivant Sciences Quarterly report: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Quarterly report: Q2 2026


Roivant Sciences Earnings release: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Earnings release: Q2 2026


Roivant Sciences Slides: Q2 2026

Nov 10, 2025, 8:00 AM EST - 7 months ago

Roivant Sciences Slides: Q2 2026


Roivant Sciences Transcript: Study Result

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Roivant Sciences Transcript: Study Result


Roivant Sciences Press release: Study Result

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Roivant Sciences Press release: Study Result


Roivant Sciences Slides: Study Result

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Roivant Sciences Slides: Study Result


Roivant Sciences Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 9 months ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Press release: Study Update

Sep 3, 2025, 4:30 PM EDT - 9 months ago

Roivant Sciences Press release: Study Update


Roivant Sciences Slides: Study Update

Sep 3, 2025, 4:30 PM EDT - 9 months ago

Roivant Sciences Slides: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Earnings Call Transcript: Q1 2026


Roivant Sciences Quarterly report: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Quarterly report: Q1 2026


Roivant Sciences Earnings release: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Earnings release: Q1 2026


Roivant Sciences Slides: Q1 2026

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Roivant Sciences Slides: Q1 2026


Roivant Sciences Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Roivant Sciences Proxy statement: Proxy Filing


Roivant Sciences Proxy statement: Proxy Filing

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Roivant Sciences Proxy statement: Proxy Filing


Roivant Sciences Transcript: Status Update

Jun 17, 2025, 1:00 PM EDT - 1 year ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Slides: Status Update

Jun 17, 2025, 1:00 PM EDT - 1 year ago

Roivant Sciences Slides: Status Update


Roivant Sciences Earnings Call Transcript: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q4 2025


Roivant Sciences Annual report: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Annual report: Q4 2025


Roivant Sciences Earnings release: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings release: Q4 2025


Roivant Sciences Slides: Q4 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Q4 2025


Roivant Sciences Transcript: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Press release: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Press release: Status Update


Roivant Sciences Slides: Status Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Status Update


Roivant Sciences Earnings Call Transcript: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q3 2025


Roivant Sciences Quarterly report: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Quarterly report: Q3 2025


Roivant Sciences Earnings release: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings release: Q3 2025


Roivant Sciences Slides: Q3 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Roivant Sciences Slides: Q3 2025


Roivant Sciences Slides: FY 2025

Jan 13, 2025, 5:15 PM EST - 1 year ago

Roivant Sciences Slides: FY 2025


Roivant's lung disease drug fails mid-stage trial

Dec 3, 2024, 7:19 AM EST - 1 year ago

Roivant's lung disease drug fails mid-stage trial


Roivant Sciences Earnings Call Transcript: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings Call Transcript: Q2 2025


Roivant Sciences Quarterly report: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Quarterly report: Q2 2025


Roivant Sciences Earnings release: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Earnings release: Q2 2025


Roivant Sciences Slides: Q2 2025

Nov 12, 2024, 8:00 AM EST - 1 year ago

Roivant Sciences Slides: Q2 2025


Roivant Flips a Skin Drug to Organon

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN


Roivant Sciences Transcript: Study Update

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Transcript: Study Update


Roivant Sciences Press release: Study Update

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Press release: Study Update


Roivant Sciences Slides: Study Update

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Study Update


Roivant Sciences Earnings Call Transcript: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings Call Transcript: Q1 2025


Roivant Sciences Quarterly report: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Quarterly report: Q1 2025


Roivant Sciences Earnings release: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Earnings release: Q1 2025


Roivant Sciences Slides: Q1 2025

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Roivant Sciences Slides: Q1 2025


Roivant Sciences Proxy statement: Proxy Filing

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Proxy statement: Proxy Filing


Roivant Sciences Proxy statement: Proxy Filing

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Proxy statement: Proxy Filing


Roivant Sciences Earnings Call Transcript: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings Call Transcript: Q4 2024


Roivant Sciences Annual report: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Annual report: Q4 2024


Roivant Sciences Earnings release: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Earnings release: Q4 2024


Roivant Sciences Slides: Q4 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Q4 2024


Roivant Sciences Transcript: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Transcript: Status Update


Roivant Sciences Slides: Status Update

Apr 2, 2024, 8:00 AM EDT - 2 years ago

Roivant Sciences Slides: Status Update


Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:28 AM EDT - 2 years ago

Roivant's anti-inflammatory drug succeeds in mid-stage study


supplySHOCK
supplySHOCK Jun. 4 at 11:10 AM
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 11:42 PM
0 · Reply
DocPharm
DocPharm May. 25 at 8:46 PM
$ABUS @Heavey the premium would be too insane to go private; especially with Genevant’s worth alone 16% plus the royalty rate on 10s of billions of revenue via Genevant’s inked deals - non-Covid related (not related to Pfizer or Moderna) Then factor in Moderna settlement; likely Pfizer settlement at 2-3x; worth of Imdusiran with fast track; worth of AB-101; worth of their Covid antiviral that has activity against HIV You’re looking at way too hefty of a price tag Remember $ROIV is technically under water by about $3 on the shares they own
2 · Reply
Blueviking
Blueviking May. 24 at 11:37 AM
$ABUS $ROIV Big boyzz been sending this up and down for 2-3 years aquiring shares. They now hav 95 percent of them. Imo, close to a big run up soon, which has been their plan 2-3 years Its not coincidental!
1 · Reply
mj6534
mj6534 May. 22 at 10:41 PM
$ABUS it’s funny I looked at $ROIV forever ago at 4-5$ and was like “I should grab a few Shares. Welp we all should’ve bought them instead of ABUS considering we are being used to push them up. I hope androski realizes what a POS she is.
5 · Reply
Alfalcon
Alfalcon May. 22 at 5:44 PM
$ROIV TD Cowen raises PT >41
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
renoH4
renoH4 May. 21 at 12:38 PM
$ROIV ...and Arbutus against EBOLA ? "WORLD WAR Z" Arbutus developed LNP Technology and it was Ahead of Its Time Interestingly, Tekmira/Arbutus was one of the early pioneers of LNP technology—a technology that later became crucial for mRNA vaccines as well. The expertise gained from these Ebola programs indirectly contributed to subsequent RNA-based therapeutics and vaccine platforms. Theoretically, it would be possible to develop an adapted RNAi formulation targeting a new Ebola strain. Today, this could be accomplished even faster than it was in 2014. Hope they will find together a way and develop a medicin!
0 · Reply
Quantumup
Quantumup May. 21 at 10:33 AM
BofA⬆️ $IMVT's PT to $43 and reiterated at Buy $ROIV $ARGX JNJ LLY - INCY ABBV UCBJY AZN BofA said: We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8BN (vs. $5.5BN prior), driven by greater contribution from GD & D2T RA-both large 'white-space' TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SJD are sizable markets, we assign lower value due to higher clinical/competitive risk. We also reduce 1402 peak sales in FcRn-entrenched markets (MG, CIDP). See Exhibit 1 for updated risk-adjusted SOTP DCF. We reiterate Buy as in our view 1402's opportunity remains underappreciated.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:28 AM
$ROIV Roivant Sciences surged after swinging to profitability and moving closer to a potential brepocitinib launch. Here’s why ROIV stock suddenly became one of the most-watched biotech movers. https://globalmarketbulletin.com/is-roivant-sciences-roiv-a-good-biotech-stock-to-buy-before-its-next-fda-catalyst/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:05 AM
$ARM $ENPH $POET $ROIV $USAR These top 10 stocks are flying as investors chase massive gains in AI, biotech, solar, semiconductors, quantum computing, and rare earths. Here’s why Wall Street is suddenly paying close attention. https://globalmarketbulletin.com/top-10-stocks-delivering-big-time-gains-today/
0 · Reply
BreakoutsHappen
BreakoutsHappen May. 21 at 5:22 AM
$ROIV Stock Just Broke Out 15% on Earnings Beat and Moderna Settlement: https://breakoutshappen.com/stock-news/roiv-stock-just-broke-out-15-on-earnings-beat-and-moderna-settlement
0 · Reply
DocPharm
DocPharm May. 21 at 2:17 AM
$ROIV & $SPCX collab for the first Space based clinical trials on a large scale ? Purely speculation but I’m sure Vivek and Elon know each other well
1 · Reply
KornieAwareness7
KornieAwareness7 May. 20 at 9:59 PM
$ROIV very nice former spac as well
0 · Reply
MorganHoratio
MorganHoratio May. 20 at 8:24 PM
Today, the following 50 stocks all hit a 52-week high at some point:(11-15) eBay $EBAY Roivant Sciences $ROIV SLB $SLB Lattice Semiconductor $LSCC Fortinet $FTNT 🔥 The 52-week high club is demonstrating massive structural expansion! Capital isn't just chasing the initial AI hardware boom—it is violently rotating across multiple sectors. The fundamental quality here is immense: legacy commerce champion $EBAY has pushed past inflation headwinds to print all-time highs on retail resilience, while cybersecurity powerhouse $FTNT crushed software-slump anxieties with an explosive 20% Q1 revenue surge and record-breaking margins. Simultaneously, oil services titan $SLB is commanding a massive macro premium, up 45% YTD alone. This proves institutional smart money is strictly swarming absolute cash-flow royalty across the board. As market breadth expands into a full-scale macro rally, which of these non-megacap breakout runners holds the highest conviction for late 2026? Drop your alpha below!
0 · Reply
LewisDaKat
LewisDaKat May. 20 at 8:00 PM
$ROIV ROIV) Q4 2025 Earnings Transcript https://marketwirenews.com/stock/roiv/news/roivant-roiv-q4-2025-earnings-transcript-7695802558552145.html?utm_source=stocktwits
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 20 at 7:13 PM
$ROIV up 15% on 2.2x volume, tape grinding right into 52w highs and the bid is stacked 7x deep. Headline says arthritis drug, sure, but the actual reason this is breaking out today is sitting one layer deeper in the Q4 transcript. somebody read past page one. what'd you guys spot in the print? live tape on the breakout: https://tapeboard.com/chart/ROIV?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=roiv-bk-up-tape
0 · Reply
Alfalcon
Alfalcon May. 20 at 7:07 PM
$ROIV 59 new watcher's. Welcome
0 · Reply
bbbloo
bbbloo May. 20 at 6:57 PM
$ROIV it is funny, this stock has been steadily creeping up for awhile and then reported good results today triggering a nice price pop yet it still seems to be off people’s radar. that doesn’t bother me especially if it means that it isn’t subject to all kinds of manipulation i just find it interesting that this seems to remain so low profile. it’s going really well to attract so little attention.
0 · Reply
RunnerSignals
RunnerSignals May. 20 at 5:42 PM
stocks hitting 52-week highs today $IMVT +35% $ARM +14% $ROIV +15% $ALAB +13% $VUZI +8% new highs in a choppy market. these names are holding
0 · Reply
Quantumup
Quantumup May. 20 at 4:08 PM
Stifel reiterated $IMVT Buy; $49 ABBV LLY - INCY $ROIV $ARGX JNJ UCBJY AZN Stifel said—We are reiterating our Buy rating on IMVT following their F4Q26 report, which featured topline data from the open label Part 1 portion of their IMVT-1402 D2T RA study. Notably, while enrichment for patients with inadequate response to 2+ therapies and ACPA+ makes cross trial comparison challenging, absolute response rates of 70%+ on ACR20 look better than nipocalimab PoC data. Looking ahead, management plans to share additional updates from the program in 2H26. Meanwhile, the CLE PoC study is fully enrolled with data expected in 2H26. Finally, data in GD remain on track for next year. For the stock, we see the RA update as a solid win with the key questions moving forward focused on validation of a regulatory path and conviction in the later line commercial opportunity. At a higher level we think this bolsters the thesis for IMVT around expansion of the FcRn market into white spaces.
0 · Reply
h00man89
h00man89 May. 20 at 2:26 PM
$ROIV With lawsuit coming in long hold.
0 · Reply